Based on representations by Threshold Pharmaceuticals, Inc. that this information
qualifies as confidential commercial or financial information under the Freedom of
Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined
not to publicly disclose it. Accordingly, excluded information from the following exhibit
will not be released to the public for the time period specified:
Exhibit 10.11 through May 2, 2022
And Exhibit 10.11 is titled:
10.11*†† Amendment to License and Co-Development Agreement between the Registrant and Merck KGaA, dated December 2, 2013.
we will never know since it is confidential right? its probably some kind of deal with MERCK to sell the company at reaching certain milestone... like selling for $30 when FDA approves STS, etc.
I agree if it was bad, they need to disclose.
Hold your hats, i have a great feeling about THLD. All points to good results. I would be shocked if we get two bad PHase 3 trials in a row, esp the PC one, as the Phase II was very good with big sample. we'll get our multibagger w/ in 1.5 years at the worst imo.
The people on this board are amazing - THLD, as a public company, has a fiduciary duty to disclose all material events (positive or negative), so why would you ever assume by default that this filing amounts to a positive future event - it could equally represent, for example, a premature stoppage of a trial due to side effects. In the spirit of this board, $15 by June 2013!